​

Funding Round

Series C - 4D Molecular Therapeutics

Series C - 4D Molecular Therapeutics

Investment Firm

Overview

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Announced Date

Jun 16, 2020

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Viking Global Investors

Viking Global Investors

Viking Global Investors is a early_stage_venture and late_stage_venture firm.

Participant Investors

12

Investor Name
Participant InvestorViking Global Investors
Participant InvestorBiotechnology Value Fund
Participant InvestorCystic Fibrosis Foundation
Participant InvestorArrowMark Partners
Participant InvestorPappas Capital

Round Details and Background

4D Molecular Therapeutics raised $75000000 on 2020-06-16 in Series C

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 04, 2023
Post-IPO Equity - 4D Molecular Therapeutics
-120.0M
Feb 06, 2024
Post-IPO Equity - 4D Molecular Therapeutics
-300.0M
Sep 19, 2017
Venture Round - 4D Molecular Therapeutics
1-3.0M
Aug 13, 2015
Venture Round - 4D Molecular Therapeutics
-7.0M

Recent Activity

There is no recent news or activity for this profile.